Breaking News Instant updates and real-time market news.

NVS

Novartis

$93.63

-1.32 (-1.39%)

, AMGN

Amgen

$191.61

-1.34 (-0.69%)

13:17
04/04/19
04/04
13:17
04/04/19
13:17

Amgen sued by Novartis over Aimovig migraine drug, Reuters reports

Novartis (NVS) has filed a lawsuit against Amgen (AMGN) in Manhattan federal court, accusing Amgen of trying to back out of agreements to jointly develop and market Aimovig for the prevention of migraines and keep the profits, Reuters' Jonathan Stempel reports. According to the complaint, Novartis says it has spent several hundred million dollars on Aimovig since August 2015, when the collaboration began, and argues that Amgen's April 2 notice to end the partnership should be deemed void because it was "based on an incorrect pretext that Novartis breached the agreements when an affiliate worked with another company on a possible Aimovig rival." Reference Link

NVS

Novartis

$93.63

-1.32 (-1.39%)

AMGN

Amgen

$191.61

-1.34 (-0.69%)

  • 04

    Apr

  • 08

    Apr

  • 10

    Apr

  • 30

    Apr

NVS Novartis
$93.63

-1.32 (-1.39%)

02/20/19
MSCO
02/20/19
NO CHANGE
Target $215
MSCO
Overweight
Amgen could fall over 10% if Sandoz wins Enbrel IP case, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that a District Court verdict is expected some time in Q1 of 2019 on the ability of Novartis' (NVS) generics division Sandoz to launch their Enbrel biosimilar, Erelzi, which received FDA approval in mid-2016 but has been blocked by a preliminary injunction obtained by Amgen (AMGN). In a scenario where the court rules in favor of Amgen, he would expect upside of 3%-5% for Amgen shares and he would expect AbbVie (ABBV) to trade up 1%-2% in sympathy. If the court rules in favor of Sandoz, Harrison would expect downside of over 10% for Amgen and would expect AbbVie shares to trade down 6%-8%. If the companies announce a settlement, he would expect 1%-2% upside for Amgen and a minimal impact on AbbVie shares, Harrison tells investors. His base case view is that the ruling is likely to be in favor of Amgen, noted Harrison, who keeps an Overweight rating on Amgen.
02/25/19
BERN
02/25/19
NO CHANGE
BERN
Spark Therapeutics, Roche deal makes sense, says Bernstein
Bernstein analyst Vincent Chen notes that he has long seen Spark Therapeutics (ONCE) as a takeout candidate in gene therapy after the Wall Street Journal reported Roche (RHHBY) is near acquiring the company for close to $5B. The analyst thinks the deal makes sense as adding hemophilia gene therapy to Hemlibra sets up Roche as a leader in next-gen non-factor hemophilia drugs, CNS gene therapy pipeline is a good fit for Roche's growing neuroscience franchise, and as it serves as a cornerstone in establishing Roche as a gene therapy leader, to rival the likes of Novartis (NVS).
03/04/19
PIPR
03/04/19
NO CHANGE
PIPR
Piper Jaffray sees continued medical cannabis growth
Piper Jaffray analyst Michael Lavery writes that his discussions with a medical pain specialist in New York affirm his expectations of continued growth for medical cannabis, particularly as practitioners search for opioid alternatives. With over 30 U.S. states now in favor of medical use of marijuana, the analyst believes that the national prohibition will end in the next few years with the "STATES Act or federal legalization". Lavery is positive on Tilray (TLRY) and its partnership with Novartis (NVS) to develop and distribute medical cannabis products, keeping his Overweight rating and $90 price target on the shares. The analyst also calls GW Pharma (GWPH) a "trailblazer for developing cannabis-derived products for medical use", with its FDA-approved epidiolex cannabidiol product, keeping his Overweight rating and $195 price target on the stock. Lavery further maintains his Overweight rating and $60 price target on Canopy Growth (CGC) given its current valuation.
03/20/19
SBSH
03/20/19
NO CHANGE
SBSH
Bayer shares likely to remain 'depressed' pending trial success, says Citi
While sentiment will "clearly take a knock" at the second Roundup trial going against Bayer (BAYRY), both verdicts were delivered by juries in California and EUR 22B of litigation risk is already priced into the shares, Citi analyst Peter Verdult tells investors in a research note. The analyst says his legal checks continue to instruct him to be more focused on the upcoming Hall vs. Monsanto trial being held in St Louis from April 1. He says that verdict will better determine whether his estimate of a potential settlement liability of $1B-$6B needs to be refined. However, Bayer shares will "likely remain depressed" until there is evidence of the company prevailing in one or more of the six cases to go to trial in 2019, Verdult contends. He keeps a Buy rating on the stock but prefers other Pharma plays AstraZeneca (AZN), Sanofi (SNY), Novartis (NVS) and Merck (MRK).
AMGN Amgen
$191.61

-1.34 (-0.69%)

02/26/19
MSCO
02/26/19
NO CHANGE
Target $215
MSCO
Overweight
Morgan Stanley says Sanofi, Regeneron face 'uphill battle' in Amgen patent fight
After a Delaware district court ruled in favor of Amgen (AMGN) upholding the validity of patents on PCSK9 antibodies in litigation versus Sanofi (SNY) and Regeneron (REGN), Morgan Stanley analyst Matthew Harrison said he believes Sanofi and Regeneron face an "uphill battle" given this was the second district court trial to find in favor of Amgen. Harrison, who said he expects "no acute impact" to Amgen or Regeneron shares given the limited recent investor focus on PCSK9 uptake, keeps an Overweight rating on Amgen shares.
03/14/19
BMOC
03/14/19
INITIATION
Target $228
BMOC
Outperform
Amgen initiated with an Outperform at BMO Capital
BMO Capital analyst Do Kim initiated Amgen with an Outperform and $228 price target. Kim views shares are undervalued, and said concerns over the declining legacy franchises have overshadowed the emergent early lifecycle commercial drugs and promising late- and early-stage pipeline. The analyst views Amgen as a core biotech holding, as a stable dividend and aggressive stock buybacks provide a defensive investment, with meaningful pipeline opportunities for long-term growth.
03/15/19
03/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Simmons First National (SFNC) initiated with a Buy at DA Davidson. 2. Amgen (AMGN) and Gilead (GILD) initiated with an Outperform at BMO Capital. 3. Rocket Pharmaceuticals (RCKT) initiated with a Buy at BofA/Merrill. 4. Urovant Sciences (UROV) initiated with a Buy at SunTrust. 5. Spectrum (SPPI) assumed with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/02/19
PIPR
04/02/19
NO CHANGE
PIPR
Overweight
Inovio d-BiTEs news a 'significant pleasant surprise,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said Inovio (INO) presented what he considers interesting, "albeit preclinical," data on DNA-encoded bispecific T-cell engagers, or "d-BiTEs," that could offer the advantages of Amgen's (AMGN) BiTE technology while "also offering what we see as an elegantly simple approach to addressing the inherent half-life challenges of current BiTE technology." Raymond said he did not expect that the company would be working on DNA-encoded bispecifics and called the announcement "a significant pleasant surprise" from the American Association for Cancer Research Annual Meeting. Raymond keeps an Overweight rating on Inovio shares.

TODAY'S FREE FLY STORIES

OMC

Omnicom

$81.83

-0.47 (-0.57%)

16:51
04/22/19
04/22
16:51
04/22/19
16:51
Hot Stocks
Omnicom officer Jonathan Nelson sells over $400K in company shares »

Omnicom officer Jonathan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

CE

Celanese

$104.50

-0.7 (-0.67%)

16:50
04/22/19
04/22
16:50
04/22/19
16:50
Hot Stocks
Celanese reports Q1 EBIT $421M vs. $474M last year »

Reports Q1 operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

CE

Celanese

$104.50

-0.7 (-0.67%)

16:49
04/22/19
04/22
16:49
04/22/19
16:49
Hot Stocks
Celanese CEO sees Q2 conditions similar to Q1 »

CEO Mark Rohr says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

CE

Celanese

$104.50

-0.7 (-0.67%)

16:48
04/22/19
04/22
16:48
04/22/19
16:48
Earnings
Celanese backs FY19 EPS view of about $10.50, consensus $10.37 »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

CE

Celanese

$104.50

-0.7 (-0.67%)

16:46
04/22/19
04/22
16:46
04/22/19
16:46
Earnings
Celanese reports Q1 adjusted EPS $2.62, consensus $2.41 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

SIMO

Silicon Motion

$42.15

-0.52 (-1.22%)

16:44
04/22/19
04/22
16:44
04/22/19
16:44
Downgrade
Silicon Motion rating change  »

Silicon Motion cut to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 28

    May

TSLA

Tesla

$262.90

-10.35 (-3.79%)

16:42
04/22/19
04/22
16:42
04/22/19
16:42
Hot Stocks
Tesla CEO sees Robotaxis on the road in 2020 »

Says cost of Robotaxi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

16:39
04/22/19
04/22
16:39
04/22/19
16:39
Conference/Events
SunTrust gov't affairs analysts to hold an analyst/industry conference call »

Analysts hold an…

BA

Boeing

$375.02

-5 (-1.32%)

, TSLA

Tesla

$262.90

-10.35 (-3.79%)

16:38
04/22/19
04/22
16:38
04/22/19
16:38
On The Fly
Fly Intel: Wall Street's top stories for Monday »

The major averages were…

BA

Boeing

$375.02

-5 (-1.32%)

TSLA

Tesla

$262.90

-10.35 (-3.79%)

KMB

Kimberly-Clark

$130.24

6.76 (5.47%)

GWW

Grainger

$291.05

-17.215 (-5.58%)

SSNLF

Samsung

$0.00

(0.00%)

KEYW

KEYW

$11.16

3.31 (42.17%)

JEC

Jacobs Engineering

$78.69

1.755 (2.28%)

AKRX

Akorn

$2.98

0.21 (7.58%)

EAF

GrafTech

$12.35

-1.58 (-11.34%)

ISRG

Intuitive Surgical

$490.70

-37.34 (-7.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 22

    Apr

  • 22

    Apr

  • 22

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 29

    Apr

  • 29

    Apr

  • 01

    May

  • 01

    May

  • 01

    May

  • 02

    May

  • 03

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 09

    May

  • 20

    May

  • 29

    May

  • 05

    Jun

TSLA

Tesla

$262.90

-10.35 (-3.79%)

16:38
04/22/19
04/22
16:38
04/22/19
16:38
Hot Stocks
Tesla CEO sees Model S/3/X production of 10,000/wk in 2019 »

Sees reaching Model S,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

LENS

Presbia

$0.56

-0.0034 (-0.61%)

16:38
04/22/19
04/22
16:38
04/22/19
16:38
Hot Stocks
Breaking Hot Stocks news story on Presbia »

Presbia trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDR

Alder Biopharmaceuticals

$12.77

0.1 (0.79%)

16:36
04/22/19
04/22
16:36
04/22/19
16:36
Hot Stocks
Alder Biopharmaceuticals: FDA accepts for review the BLA for eptinezumab »

Alder BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

GPC

Genuine Parts

$103.62

-1.84 (-1.74%)

16:33
04/22/19
04/22
16:33
04/22/19
16:33
Hot Stocks
Genuine Parts CEO Paul Donahue to also serve as board chairman »

Genuine Parts announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

TSLA

Tesla

$262.90

-10.35 (-3.79%)

16:32
04/22/19
04/22
16:32
04/22/19
16:32
Hot Stocks
Tesla says Autopilot observes driver, pedestrian tendencies »

Says Autopilot uses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

HSTM

HealthStream

$27.23

0.11 (0.41%)

16:32
04/22/19
04/22
16:32
04/22/19
16:32
Earnings
HealthStream backs FY19 revenue view $251M-$258M, consensus $255.84M »

Raises FY19 CapEx view to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 28

    May

HSTM

HealthStream

$27.23

0.11 (0.41%)

16:31
04/22/19
04/22
16:31
04/22/19
16:31
Earnings
HealthStream reports Q1 EPS 15c, consensus 7c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 28

    May

RCKT

Rocket Pharmaceuticals

$17.78

0.91 (5.39%)

16:31
04/22/19
04/22
16:31
04/22/19
16:31
Initiation
Rocket Pharmaceuticals initiated  »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GES

Guess

$16.66

-0.41 (-2.40%)

16:30
04/22/19
04/22
16:30
04/22/19
16:30
Hot Stocks
Breaking Hot Stocks news story on Guess »

Guess down 3.9% at $16…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
04/22/19
04/22
16:30
04/22/19
16:30
Options
Preliminary option volume of 15.3M today »

Preliminary option volume…

GRTS

Gritstone Oncology

$14.57

0.86 (6.27%)

16:29
04/22/19
04/22
16:29
04/22/19
16:29
Syndicate
Gritstone Oncology files to sell 6.5M shares of common stock »

Goldman Sachs & Co.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACC

American Campus

$46.47

-0.87 (-1.84%)

16:28
04/22/19
04/22
16:28
04/22/19
16:28
Earnings
American Campus reports Q1 FFO 69c, consensus 65c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 01

    May

GES

Guess

$16.66

-0.41 (-2.40%)

16:26
04/22/19
04/22
16:26
04/22/19
16:26
Hot Stocks
Guess to initiate $150M stock buyback »

Guess intends to initiate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GES

Guess

$16.66

-0.41 (-2.40%)

16:26
04/22/19
04/22
16:26
04/22/19
16:26
Syndicate
Guess to offer $250M in convertible senior notes »

The company states the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHE

Regional Health Properties

$2.26

1.17 (107.34%)

16:26
04/22/19
04/22
16:26
04/22/19
16:26
Hot Stocks
Regional Health Properties not in compliance with NYSE listing rules »

Regional Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBL

BHP Billiton plc

$48.94

0.225 (0.46%)

16:24
04/22/19
04/22
16:24
04/22/19
16:24
Downgrade
BHP Billiton plc rating change  »

BHP Billiton plc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.